pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen receptor-positive (ER+), HER2– locally advanced/metastatic BC (LA/mBC) with resistance to prior adjuvant (adj) endocrine therapy (ET).
Year: 2024
Type: conference-abstract
Source: Journal of Clinical Oncology
Institutions: Winship Cancer Institute, Dana-Farber Cancer Institute, Vall d'Hebron Institute of Oncology, Universitätsklinikum Erlangen, Comprehensive Cancer Center Erlangen, Hospital Alemán, Asan Medical Center, University of Ulsan, F. Hoffmann-La Roche AG, National Taiwan University Hospital, Genentech, Institute of Cancer Research, Humanitas University, Institut Gustave Roussy
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Roche
OpenAlex ID: W4399324273